GlassScriptPhysician profile
Gaurav Banka
NPI 1205129731
$3,046.97
in general payments reported to CMS, 2019-2025
25 companies · $891 in 2025
The $891 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $249 · 2021: $61.12 · 2022: $145 · 2023: $384 · 2024: $560 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $582.61 | 2019-2025 | |
| Pfizer INC. | $454.87 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $323.39 | 2023-2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $295.50 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $178.69 | 2019-2024 | Watchman Flx, Eluvia, Bodyguardian |
| Abbott Laboratories | $139.34 | 2020-2024 | Mitraclip |
| Amgen INC. | $135.56 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.76 | 2022-2025 | Lifevest |
| Akcea Therapeutics, INC. | $94.33 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $86.24 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.70 | 2023-2025 | Jardiance |
| Inspire Medical Systems, INC. | $82.54 | 2025 | Inspire |
| Kestra Medical Technology Services, INC. | $67.08 | 2023-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $53.77 | 2024-2025 | Eliquis, Camzyos |
| Bridgebio Pharma, INC. | $50.34 | 2025 | Attruby |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $47.44 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $47.40 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $46.01 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $35.22 | 2019 | |
| Altathera Pharmaceuticals LLC | $29.54 | 2025 | Sotalol Hydrochloride |
| Cleerly, INC. | $23.02 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Merck Sharp & Dohme LLC | $22.41 | 2025 | Verquvo |
| Bsn Medical INC | $18.44 | 2020 | |
| Electromed, INC. | $17.14 | 2023 | Smartvest |
| Edwards Lifesciences Corporation | $13.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurav Banka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.